Pregnant women in rural Appalachia face an 11.94% hepatitis C virus infection rate—5 times the state average—revealing a pressing public health concern that demands increased treatment opportunities.
Hepatitis C virus (HCV) presents a significant public health issue, although findings from a recent study are calling attention to its disproportionate impact on pregnant women in rural populations.1
Conducted at a single tertiary care clinic in Appalachia, results from the retrospective cohort study called attention to an 11.94% HCV infection rate and a 17.8% preterm birth rate, both significantly greater than the national average and indicative of the need for increased treatment opportunities in this population with continuity of care challenges.1
Hepatitis C virus (HCV) presents a significant public health issue, affecting an estimated 58 million people worldwide. This burden is especially pronounced in reproductive-aged adults, supporting the US Center for Disease Control and Prevention’s HCV screening recommendation for all pregnant people. Identifying HCV in this patient population allows them to access treatment and identifies at-risk infants in need of testing and ongoing monitoring, yet many patients still go untested and thus untreated.2,3
“HCV as a precursor to preterm labor has received recent attention,” wrote Byron Calhoun, MD, professor and vice-chair in the department of obstetrics and gynecology at West Virginia University-Charleston, and colleagues.1 “Most studies focus on inner-city populations and have not explored the opioid epidemic's impact in rural regions.”
To address this gap in research, investigators assessed the prevalence of HCV in a cohort of pregnant women receiving prenatal care at a single tertiary care clinic in Appalachia and conducted further analyses to determine its association with preterm birth, defined as gestation <37 weeks. Data on HCV status, viral load, preterm birth, and maternal characteristics and morbidity were retrospectively collected from pregnant patients universally screened for HCV between 2017 and 2021, excluding those with multiple gestations and uterine anomalies.1
Among the total study cohort, the HCV infection rate was 11.94% (119.4 per 1000), which investigators pointed out is 5 times the rate of 22.6 per 1000 live births in West Virginia in 2014 and 35 times the national rate of 3.4 per 1000 live births. Viral loads were detected in 6.38% of patients.1
Investigators pointed out patients in the HCV-positive group (n = 92) were older than those in the HCV-negative group (n = 628) (38.9 years of age vs 26.9 years of age; P <.001) and had lower rates of obesity (8.7% vs 31.2%, respectively; P <.001).1
A total of 720 patients had birth outcome data available, of which 326 (45.3%) had high rates of tobacco use and 189 (26.3%) had substance abuse. The preterm birth rate was 17.8%, nearly double the national average (10.09%).1
Although the HCV-positive group had significantly greater rates of tobacco use (78.3% vs 40.4%; P <.001) and substance use (63.0% vs 24.0%; P <.001), investigators noted there was no significant difference in preterm birth compared to the HCV-negative group (16.3% vs 18.0%; P = .534).1
“While there have been studies showing an association between HCV and [preterm birth], our study showed no statistically significant difference in [preterm birth] rates between HCV-positive and HCV-negative patients. This may be attributable to high incidence of [preterm birth] contributory factors in the study population,” investigators concluded.1
This article was initially published by our sister publication HCP Live.
References:
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Improved maternal cardiac arrest management reported from Obstetric Life Support training
November 19th 2024A study found that Obstetric Life Support education significantly improves health care providers' readiness and outcomes in maternal cardiac arrest management, advocating for broader implementation.
Read More